Lipella Pharmaceuticals Inc. Common Stock Total Assets
Lipella Pharmaceuticals Inc. Common Stock total assets. Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) holds total assets worth $2.35 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Lipella Pharmaceuticals Inc. Common Stoc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
Total assets of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See today's stock price for Lipella Pharmaceuticals Inc. Common Stoc for real-time trading data and today's change.
Lipella Pharmaceuticals Inc. Common Stock - Asset Composition Analysis
Lipella Pharmaceuticals Inc. Common Stock Total Assets Breakdown (December 2024)
Lipella Pharmaceuticals Inc. Common Stock total assets breakdown as of December 2024. Lipella Pharmaceuticals Inc. Common Stock's total assets of $2.35 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.7% |
| Accounts Receivable | $84.71K | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore LIPO net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipella Pharmaceuticals Inc. Common Stock's current assets represent 97.9% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 81.7% of total assets in 2024, up from 21.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Total Assets
Key competitors of Lipella Pharmaceuticals Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Lipella Pharmaceuticals Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.24 | 2.97 | 5.31 |
| Quick Ratio | 3.24 | 3.01 | 5.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.44 Million | $1.38 Million | $1.47 Million |
Lipella Pharmaceuticals Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Lipella Pharmaceuticals Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -25.3% |
| Total Assets | $2.67 Million |
| Market Capitalization | $2.31K USD |
Valuation Analysis
Below Book Valuation: The market values Lipella Pharmaceuticals Inc. Common Stock's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lipella Pharmaceuticals Inc. Common Stock's assets decreased by 25.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual total assets of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.67 Million | -25.25% |
| 2023-12-31 | $3.58 Million | -39.88% |
| 2022-12-31 | $5.95 Million | +195.60% |
| 2021-12-31 | $2.01 Million | +110.77% |
| 2020-12-31 | $955.02K | +703.10% |
| 2019-12-31 | $118.92K | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more